Overview
No overview information available.
Indication
用于经过标准治疗失败的、不可切除或转移性高度微卫星不稳定型（MSI-H）成人晚期实体瘤患者。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/03/25 | Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | ||
2025/03/06 | Phase 2 | Recruiting | |||
2025/02/27 | Phase 1 | Recruiting | Shanghai Henlius Biotech | ||
2025/01/17 | N/A | Recruiting | |||
2024/12/11 | Phase 2 | Recruiting | |||
2024/12/04 | Phase 1 | Recruiting | Guangzhou FineImmune Biotechnology Co., LTD. | ||
2024/11/18 | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | ||
2024/09/19 | Phase 2 | Recruiting | |||
2024/08/29 | Phase 2 | Recruiting | Xijing Hospital | ||
2024/07/31 | Phase 2 | Not yet recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 2/3/2025 | ||
Authorised | 2/3/2025 | ||
Authorised | 2/3/2025 | ||
Authorised | 2/3/2025 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Serplulimab Injection | 国药准字S20220013 | 生物制品 | 注射剂 | 3/22/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.